Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.

MLA

Luo, Shaohong, et al. “Cost-Effectiveness Analysis of Bevacizumab for Cerebral Radiation Necrosis Treatment Based on Real-World Utility Value in China.” Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al], vol. 200, no. 9, Sept. 2024, pp. 805–14. EBSCOhost, https://doi.org/10.1007/s00066-024-02242-6.

APA

Luo, S., Lai, S., Wu, Y., Hong, J., Lin, D., Lin, S., Huang, X., Xu, X., & Weng, X. (2024). Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China. Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al], 200(9), 805–814. https://doi.org/10.1007/s00066-024-02242-6

Chicago

Luo, Shaohong, Shufei Lai, Yajing Wu, Jinsheng Hong, Dong Lin, Shen Lin, Xiaoting Huang, Xiongwei Xu, and Xiuhua Weng. 2024. “Cost-Effectiveness Analysis of Bevacizumab for Cerebral Radiation Necrosis Treatment Based on Real-World Utility Value in China.” Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al] 200 (9): 805–14. doi:10.1007/s00066-024-02242-6.